Anuradha S. Budhu, Ph.D.

Anuradha S. Budhu, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Laboratory of Human Carcinogenesis


Dr. Budhu's research focuses on genome-scale analyses of human liver cancer. Her work on gene, microRNA and metabolite profiling, has led to the identification of important signaling molecules that underlie liver cancer biology, with applications to the clinical management of liver cancer. Dr. Budhu helps to lead a basic/translational research program, emphasizing the discovery of diagnostic, prognostic and predictive biomarkers of liver cancer. These functional genomics investigations utilize bioinformatics and molecular biology, in concert with national/international epidemiological cohorts and clinical studies. Dr. Budhu received her Ph.D. at Cornell University.  She is the Program Manager for the NCI CCR Liver Cancer Program and a Senior Associate Scientist in the Laboratory of Human Carcinogenesis.

Areas of Expertise

Functional Cancer Genomics
Hepatocellular Carcinoma
Systems Biology
Molecular Biology

CCR Liver Cancer Program

A multidisciplinary research network dedicated to improving early detection, diagnosis, prognosis and treatment of liver cancer.


Selected Key Publications

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, Wang XW
Cell Reports Medicine. 4/6: 101052, 2023.
Full-Text Article
[ Journal Article ]

Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes

Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, Wang XW.
Gastroenterology. 144: 1066-1075.e1, 2013. [ Journal Article ]

MicroRNA expression, survival, and response to interferon in liver cancer

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW.
N Engl J Med. 361: 1437-47, 2009. [ Journal Article ]

Identification of metastasis-related microRNAs in hepatocellular carcinoma

Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW.
Hepatology. 47: 897-907, 2008. [ Journal Article ]

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment

Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW.
Cancer Cell. 10: 99-111, 2006. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Cancer Cell Cover July 2017 - Tiger

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma

Published Date

About the Cover:  The Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) Consortium (depicted as a tiger) emerges from foliage, representing molecular, clinical, and epidemiological studies from teams in the United States, Thailand, and Japan, to generate a multilayered genomic and genetic liver cancer data ecosystem (represented by the tiger’s tail). Although common molecular subtypes (depicted as bamboo stalks) are observed among liver cancer types, there are differences observed between Asian and Caucasian populations (depicted by different bamboo colors). Cover art by Ethan Tyler.

Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We identified common molecular subtypes linked to similar prognosis among 199 Thai ICC and HCC patients through systems integration of genomics, transcriptomics, and metabolomics. While ICC and HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype is linked to obesity, T cell infiltration, and bile acid metabolism. These molecular subtypes are found in 582 Asian, but less so in 265 Caucasian patients. Thus, Asian ICC and HCC, while clinically treated as separate entities, share common molecular subtypes with similar actionable drivers to improve precision therapy.


Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium. Cancer Cell. 2017 Jul 10;32(1):57-70.